The Other Side: COVID's Impact on Clinical Trials with Deloitte & Philip Adamson

Clinical trials have been critically impacted throughout the past 7 months, Innovation has hit a speed bump.
In our series with Deloitte, I spoke with Douglas Billings, Managing Director at Deloitte and Philip Adamson, Chief Medical Officer at Abbott leading the Heart Failure Programs. We discussed the dynamics of how organizations like Abbott are navigating the landscape.
Some emerging tech companies as well as strategics are finding the seams in the system and partnering with healthcare partners to get the clinical trial mechanisms back on track.
Where there is a will there is a way.
Full session below.